Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutch-Belgian pediatric AML protocol based on NOPHO-AML 2004
2009-014462-26Phase 3Completed
- Sponsor
- Ghent University Hospital
- Start
- Feb 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cytarabine, etoposide, idarubicin, mitoxantrone, tioguanine and 2 more in acute myeloid leukemia (AML), sponsored by Ghent University Hospital. Primary endpoints: Complete remission achievement and Reasons for failure to achieve CR. Started Feb 2010; status: completed.
02
Drugs
cytarabineetoposideidarubicinmitoxantronetioguanine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-014462-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014462-26.